1. Treatment

    Comments Leave a Comment

    1-15 of 378 1 2 3 4 ... 24 25 26 »
    1. Mentioned In 378 Articles

    2. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      ...aging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery....
      Read Full Article
    3. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2{alpha} to tumor suppression [Medical Sciences]

      ...l-cycle gene expression. A small-molecule inhibitor of HIF2α activity diminishes the tumor response to AZA+RA treatment, indicating that the increase in HIF2α levels is a key component in tumor response to AZA+RA. The li...
      Read Full Article
    4. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies
      ...ymphomas, brain tumors, and histiocytoses—that no longer respond to standard treatment or have recurred after treatment. “Pediatric MATCH is a very special trial,” said Douglas R. Lowy, M.D., NCI acting director. “There ...
      Read Full Article
      Mentions: Treatment COG
    5. MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      ... in diagnosis in three patients. Fourteen patients received 17 targeted therapies; two had received a matched treatment prior to inclusion.

      Conclusions: Research biopsies are feasible in advanced pediatric mal...
      Read Full Article
      Mentions: Treatment
    6. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      .... However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma. The muti-drug resistance-associated protein (MRP), which enc...
      Read Full Article
    7. Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma.

      ...an-nanoceria with curcumin, each demonstrated to have anti-cancer properties, were synthesized and applied as treatment for human childhood neuroblastoma. The anti-cancer activities of these formulations were explored in...
      Read Full Article
      Mentions: Treatment MYCN
    8. 1-15 of 378 1 2 3 4 ... 24 25 26 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Treatment

    1. It is an important clinical problem because it presents a paradoxical dilemma that while cranial-spinal radiation is needed to cure many childhood cancers, an unfortunate consequence is that 10-to-15-years following radiation treatment some survivors develop meningiomas.
      In Brain tumor scientists map mutation that drives tumors in childhood cancer survivors
    2. Our paper gives us some clues as to predictive biomarkers of who might respond best to this type of treatment.
      In Combining immunotherapies effective against mouse model of cancer
    3. It is an important clinical problem because it presents a paradoxical dilemma that while cranial-spinal radiation is needed to cure many childhood cancers, an unfortunate consequence is that 10-to-15-years following radiation treatment some survivors develop meningiomas.
      In Mapping mutations that drive tumours in childhood cancer survivors